FAVALLI, ENNIO GIULIO
FAVALLI, ENNIO GIULIO
Dipartimento di Scienze Cliniche e di Comunità
Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry
2024 A. Manfredi, M. Fornaro, C. Bazzani, S. Perniola, A. Cauli, A. Rai, E.G. Favalli, S. Bugatti, M. Rossini, R. Foti, F. Conti, G. Lopalco, A. Scalvini, C. Garufi, M. Congia, R. Gorla, E. Gremese, F. Atzeni, R. Caporali, F. Iannone, M. Sebastiani
Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission
2023 R. Giacomelli, R. Caporali, F. Ciccia, S. Colafrancesco, L. Dagna, M. Govoni, F. Iannone, P. Leccese, C. Montecucco, G. Pappagallo, G. Pistone, R. Priori, P. Ruscitti, P. Sfriso, L. Cantarini, N. Belfiore, C. Bernardi, M. Gabini, S. Bettio, A. Brucato, G. Italiano, F.P. Cantatore, D. Iacono, I. Pantano, E. Tirri, F. Ursini, A.L. Monaco, F. Caso, L. Quartuccio, M.S. Chimenti, A. Gattamelata, E. Gremese, M. Paroli, A. Picchianti-Diamanti, G.D. Sebastiani, E. Favalli, A. Sulli, M. Frassi, P. Faggioli, R. Foti, C. Campochiaro, G. Cavalli, A. Tomelleri, M. Manara, L. De Stefano, R. De Angelis, S. Parisi, G. Lopalco, M. Piga, D. Marotto, M. Colaci, A. Padula, G. Guggino, G. Emmi, C. Baldini, J. Sota, A. Vitale, A. Berti, E. Bartoloni, C. Grava, S. Bindoli, R. Vitetta
Rheumatoid Arthritis from Easy to Complex Disease: From the “2022 GISEA International Symposium”
2023 S. Perniola, M.S. Chimenti, F.R. Spinelli, B. Frediani, R. Foti, S. Ferrigno, C. Garufi, G. Cassone, V. Venerito, F. Atzeni, R. Caporali, F. Conti, E.G. Favalli, F. Iannone, M. Sebastiani, G.F. Ferraccioli, G. Lapadula, E. Gremese
Effect of neridronate on axial involvement in patients with spondyloarthritis when biologics are not possible. Results of a monocentric study
2023 C. Crotti, R. Di Taranto, F. Orsini, M. Ferrito, M. Varenna, E.G. Favalli, R. Caporali
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
2023 L.M. Ornbjerg, K. Rugbjerg, S. Georgiadis, S.H. Rasmussen, U. Lindstrom, K. Pavelka, N. Yilmaz, E.G. Favalli, M.J. Nissen, B. Michelsen, E. Vieira-Sousa, G.T. Jones, R. Ionescu, H. Relas, C. Sanchez-Piedra, M. Tomsic, A.J. Geirsson, I. van der Horst-Bruinsma, J. Askling, A.G. Loft, L. Nekvindova, H. Direskeneli, F. Iannone, A. Ciurea, K.M. Fagerli, M.J. Santos, G.J. Macfarlane, C. Codreanu, K. Eklund, M. Pombo-Suarez, Z. Rotar, B. Gudbjornsson, T. Rusman, M. Ostergaard, M.L. Hetland
The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events
2023 E.G. Favalli, G. Cincinelli, S. Germinario, R. Di Taranto, F. Orsini, G. Maioli, M. Biggioggero, M. Ferrito, R. Caporali
Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients
2023 M. Ferrito, G. Cincinelli, M. Manara, R. Di Taranto, E.G. Favalli, R. Caporali
Tight control in patients with rheumatoid arthritis treated with targeted therapies across the COVID-19 pandemic era
2023 A.F. Luppino, G. Cincinelli, A. Orenti, P. Boracchi, E.G. Favalli, R. Caporali, F. Ingegnoli
From Bench to Bedside in Rheumatoid Arthritis from the “2022 GISEA International Symposium”
2023 A. Vitale, S. Alivernini, R. Caporali, G. Cassone, D. Bruno, L. Cantarini, G. Lopalco, M. Rossini, F. Atzeni, E.G. Favalli, F. Conti, E. Gremese, F. Iannone, G.F. Ferraccioli, G. Lapadula, M. Sebastiani
Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine
2022 F.R. Spinelli, E.G. Favalli, C. Garufi, M. Cornalba, S. Colafrancesco, F. Conti, R. Caporali
Secukinumab efficacy in patients with PsA is not dependent on patients' body mass index
2022 I. Pantano, D. Iacono, E.G. Favalli, G. Scalise, L. Costa, F. Caso, G. Guggino, R. Scarpa, F. Ciccia
Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review
2022 I.E. van der Horst-Bruinsma, P.C. Robinson, E.G. Favalli, F.D. Verbraak, M. Kim, T. Kumke, L. Bauer, B. Hoepken, A. Deodhar
The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
2022 E.G. Favalli, A. Gobbini, M. Bombaci, G. Maioli, M. Biggioggero, E. Pesce, A. Favalli, M. Martinovic, T. Fabbris, E. Marchisio, A. Bandiera, A. Gori, S. Abrignani, R. Grifantini, R. Caporali
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations
2022 A. Favalli, E.G. Favalli, A. Gobbini, E. Zagato, M. Bombaci, G. Maioli, E. Pesce, L. Donnici, P. Gruarin, M. Biggioggero, S. Curti, L. Manganaro, E. Marchisio, V. Bevilacqua, M. Martinovic, T. Fabbris, M.L. Sarnicola, M. Crosti, L. Marongiu, F. Granucci, S. Notarbartolo, A. Bandera, A. Gori, R. De Francesco, S. Abrignani, R. Caporali, R. Grifantini
Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis
2022 S. Bugatti, L. De Stefano, B. D'Onofrio, A. Nicrosini, E. Mauric, M. Di Lernia, G. Sakellariou, E.G. Favalli, A. Manzo, R. Caporali, C. Montecucco
Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis
2022 G. Maioli, R.F. Caporali, E.G. Favalli
Real-world 6 and 12-month drug retention, remission and response rates of secukinumab in 2,017 psoriatic arthritis patients in 13 European countries
2022 B. Michelsen, S. Georgiadis, D. Di Giuseppe, A.G. Loft, M.J. Nissen, F. Iannone, M. Pombo-Suarez, H. Mann, Z. Rotar, K.K. Eklund, T.K. Kvien, M.J. Santos, B. Gudbjornsson, C. Codreanu, S. Yilmaz, J.K. Wallman, C.H. Brahe, B. Möller, E.G. Favalli, C. Sánchez-Piedra, L. Nekvindova, M. Tomsic, N. Trokovic, E.K. Kristianslund, H. Santos, T.J. Löve, R. Ionescu, Y. Pehlivan, G.T. Jones, I. van der Horst-Bruinsma, L.M. Ørnbjerg, M. Østergaard, M.L. Hetland
Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium
2022 F. Ceccarelli, M. Govoni, M. Piga, G. Cassone, F.P. Cantatore, G. Olivieri, A. Cauli, E.G. Favalli, F. Atzeni, E. Gremese, F. Iannone, R. Caporali, M. Sebastiani, G.F. Ferraccioli, G. Lapadula, F. Conti
Axial Spondyloarthritis: Reshape the Future—From the “2022 GISEA International Symposium”
2022 F. Salaffi, C. Siragusano, A. Alciati, G. Cassone, S. D'Angelo, S. Guiducci, E.G. Favalli, F. Conti, E. Gremese, F. Iannone, R. Caporali, M. Sebastiani, G.F. Ferraccioli, G. Lapadula, F. Atzeni
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab : results from the Italian GISEA registry
2021 M. Sebastiani, V. Venerito, S. Bugatti, C. Bazzani, M. Biggioggero, L. Petricca, R. Foti, A. Bortoluzzi, S. Balduzzi, E. Visalli, B. Frediani, A. Manfredi, E. Gremese, E. Favalli, F. Iannone, G. Ferraccioli, G. Lapadula